english.prescrire.org > Prescrire International > N°144 - December 2013

n°144

December 2013

Issue Contents
Editorial

Free  At least two!

p.284
Regulators should recognise that one favourable trial is not enough

New Products


Meningococcal conjugate vaccine A,C,W135,Y (New Drug)

p.285-288
Immunogenic from the age of 1 year

INN common stem: cef-

p.288

Bevacizumab and relapsed ovarian cancer (New Indication)

p.289
Too many serious and life-threatening adverse effects

Rivaroxaban and pulmonary embolism (New Indication)

p.290
No better than established anticoagulant therapy

Free  Ceftaroline fosamil (New Drug)

p.291
Just another intravenous antibiotic

Adverse Effects


Drug-related cardiac valve disease

p.292-295
Can be asymptomatic for long periods

Identifying drug-related disorders: a probabilistic approach

p.293

Devil's claw root: ulcers and gastrointestinal bleeding?

p.296
This plant is best avoided

Domperidone and cardiac disorders: avoid this neuroleptic

p.297
Poor harm-benefit balance

Febuxostat: hepatic failure

p.297
No safer than allopurinol

Reviews


Treatment of ductal carcinoma in situ

p.298-303
An uncertain harm-benefit balance

Ductal carcinoma in situ: progression to invasive cancer is slow and only occurs in a minority of cases

p.301

Prescrire's advice

p.303
Ductal carcinoma in situ: calmly discuss treatment options with the patient

Outlook


Publication planning: an effective corporate strategy to influence health professionals

p.304-307
Marketing ploy

An effective publication plan: the promotion of postmenopausal hormone replacement therapy

p.305

Free  Generic bashing: effective but illegal

p.307
Very much in vogue in France

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe